Are you looking to grow an existing brand through potential new indications or to grow your portfolio through new compounds and indications?
How do you target the winners? How can you balance the opportunities and risks?
Aligning your cross-functional expertise to assess potential target opportunities in terms of clinical and regulatory feasibility and commercial attractiveness streamlines your portfolio and allows you to focus on the indications which can potentially deliver the most value - for patients and for your company.
Mirador’s portfolio prioritisation services deliver a robust process to facilitate rigorous cross functional assessment and prioritisation of potential investment pathways, that can be customised to meet your specific needs.
At Mirador we have multiple solutions that can be tailored to meet your needs: from qualitative assessments and workshops to quantitative forecasts and asset evaluation facilitating effective and robust decision making across Lifecycle Management strategy, Brand planning, Corporate strategy, Business Development and Licensing.
Our proprietary Potential Investment Categorisation (PIC) model provides a framework for objective opportunity analysis enabling you to make the right decisions regarding which opportunities to invest in and which to avoid.
At Mirador we pride ourselves in delivering a tailored approach to deliver the best outcomes for our clients. We would be very happy to discuss your needs.